Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs DexCom, Inc. (DXCM) Price & Performance

ProShares Ultra Bloomberg Natural Gas ETFTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bloomberg Natural Gas ETF vs DexCom, Inc. — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.93, while DexCom, Inc. trades at $90.44 (market cap $33.79B). The key difference: DexCom, Inc. is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.

BOILDXCM
Sector
Leveraged / InverseHealth
52-Week High
$87.24$89.53
52-Week Low
$18.74$54.84
Market Cap
$33.79B
Enterprise Value
$33.24B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bloomberg Natural Gas ETF

BOIL trades at $20.91, up 0.97% with a bearish technical signal as moving averages indicate selling pressure. The stock recently underwent a 1:2 split effective May 28, 2026. Natural gas market volatility and weather-driven demand fluctuations create trading opportunities, though financial fundamentals remain undisclosed in current data.

Outlook hinges on natural gas price movements and energy sector dynamics. Investment appeal lies in leveraged exposure to gas futures via the ETF structure, but risks include commodity price swings and lack of traditional corporate fundamentals. Bearish technicals suggest cautious entry points near support at $20.

DexCom, Inc.

DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.

The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.

Returns comparison

Trailing returns across standard periods

About ProShares Ultra Bloomberg Natural Gas ETF

BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.

Read more on BOIL

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM